Brii Ups Its Bet On VBI’s Hepatitis B Assets Amid Larger Treatment, Prevention Push

The two companies have partnered on VBI-2601 since 2018, and Brii is now taking global rights to that program as well as licensing rights to VBI’s hepatitis B vaccine.

Brii is in-licensing VBI's hepatitis B vaccine • Source: Shutterstock

Brii Biosciences is expanding the scope of its license for an investigational hepatitis B virus (HBV) immunotherapy drug and taking on an HBV vaccine in its more than four-year-old partnership with VBI Vaccines Inc., months after Phase II data for the drug demonstrated promising tolerability and antibody responses.

The two companies said 5 July that Brii Bio would expand its exclusive license for the HBV drug, VBI-2601/BRII-179, from...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.